Abstract
An important limitation of recombinant adeno-associated virus (rAAV) vector efficiency is the requirement of hostcell-mediated synthesis of double-stranded DNA from the single-stranded genome. We have bypassed this step in a specialized self-complementary rAAV (scAAV) vector, by utilizing the tendency of AAV to package DNA dimers when the replicating genome is half the length of the wild type (wt). To produce these vectors efficiently, we have deleted the terminal resolution site (trs) from one rAAV TR, preventing the initiation of replication at the mutated end. These constructs generate single-stranded, inverted repeat genomes, with a wt TR at each end, and a mutated TR in the middle. After uncoating, the viral DNA folds through intramolecular base pairing within the mutant TR, which then proceeds through the genome to form a double-stranded molecule. We have used the scAAV to investigate barriers to rAAV transduction in the mouse liver, muscle and brain. In each tissue, scAAV was characterized by faster onset of gene expression and higher transduction efficiency. This study confirms earlier predictions that complementary-strand DNA synthesis is the primary barrier to rAAV-2 transduction. The scAAV is unaffected by this barrier, and provides an extremely efficient vector for gene transfer into many types of cells in vivo.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
McCarty DM, Monahan PE, Samulski RJ . Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis. Gene Therapy 2001; 8: 1248–1254.
Chapman MS, Rossmann MG . Single-stranded DNA–protein interactions in canine parvovirus. Structure 1995; 3: 151–162.
King JA, Dubielzig R, Grimm D, Kleinschmidt JA . DNA helicase-mediated packaging of adeno-associated virus type 2 genomes into preformed capsids. EMBO J 2001; 20: 3282–3291.
Ferrari FK, Samulski T, Shenk T, Samulski RJ . Second-strand synthesis is a rate limiting step for efficient transduction by recombinant adeno-associated virus vectors. J Virol 1996; 70: 3227–3234.
Fisher KJ et al. Transduction with recombinant adeno-associated virus for gene therapy is limited by leading-strand synthesis. J Virol 1996; 70: 520–532.
Nakai H, Storm TA, Kay MA . Recruitment of single-stranded recombinant adeno-associated virus vector genomes and intermolecular recombination are responsible for stable transduction of liver in vivo. J Virol 2000; 74: 9451–9463.
Snyder RO et al. Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors. Nat Genet 1997; 16: 270–276.
Miao CH et al. Nonrandom transduction of recombinant adeno-associated virus vectors in mouse hepatocytes in vivo: cell cycling does not influence hepatocyte transduction. J Virol 2000; 74: 3793–3803.
Yang GS et al. Virus-mediated transduction of murine retina with adeno-associated virus: effects of viral capsid and genome size. J Virol 2002; 76: 7651–7660.
Hirata RK, Russell DW . Design and packaging of adeno-associated virus gene targeting vectors. J Virol 2000; 74: 4612–4620.
Dong JY, Fan PD, Frizzell RA . Quantitative analysis of the packaging capacity of recombinant adeno-associated virus. Hum Gene Ther 1996; 7: 2101–2112.
Chen H et al. Gene transfer and expression in oligodendrocytes under the control of myelin basic protein transcriptional control region mediated by adeno-associated virus. Gene Therapy 1998; 5: 50–58.
Chen H, McCarty DM, Bruce AT, Suzuki K . Oligodendrocyte-specific gene expression in mouse brain: use of a myelin-forming cell type-specific promoter in an adeno-associated virus. J Neurosci Res 1999; 55: 504–513.
Snyder RO et al. Features of the adeno-associated virus origin involved in substrate recognition by the viral Rep protein. J Virol 1993; 67: 6096–6104.
Wang L et al. Sustained expression of therapeutic level of factor IX in hemophilia B dogs by AAV-mediated gene therapy in liver. Mol Ther 2000; 1: 154–158.
Li J, Samulski RJ, Xiao X . Role for highly regulated rep gene expression in adeno-associated virus vector production. J Virol 1997; 71: 5236–5243.
Xiao X, Li J, Samulski RJ . Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J Virol 1998; 72: 2224–2232.
Zolotukhin S et al. Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Therapy 1999; 6: 973.
McCown TJ et al. Differential, persistent expression patterns of CNS gene transfer by an adeno-associated virus (AAV) vector. Brain Res 1996; 713: 99–107.
Fu H et al. Neurological correction of lysosomal storage in a mucopolysaccharidosis IIIB mouse model by adeno-associated virus-mediated gene delivery. Mol Ther 2002; 5: 42–49.
Franklin KBJ, Paxinos G . The Mouse Brain in Stereotaxic Coordinates. Acedemic Press: San Diego, 1997.
Acknowledgements
We thank Jenifer Naspinski for technical assistance. This work was supported by NIH Grants PO1-HL66973-01 and PO1-HL51818-06. PEM was supported in part by NIH HL 03960.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
McCarty, D., Fu, H., Monahan, P. et al. Adeno-associated virus terminal repeat (TR) mutant generates self-complementary vectors to overcome the rate-limiting step to transduction in vivo. Gene Ther 10, 2112–2118 (2003). https://doi.org/10.1038/sj.gt.3302134
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.gt.3302134
Keywords
This article is cited by
-
AAV-based in vivo gene therapy for neurological disorders
Nature Reviews Drug Discovery (2023)
-
A pilot study to determine the optimal dose of scAAVIL-1ra in a large animal model of post-traumatic osteoarthritis
Gene Therapy (2023)
-
Optimization of miR-22 expression cassette for rAAV delivery on diabetes
Molecular Biomedicine (2022)
-
PEG-mediated transduction of rAAV as a platform for spatially confined and efficient gene delivery
Biomaterials Research (2022)
-
CRISPR somatic genome engineering and cancer modeling in the mouse pancreas and liver
Nature Protocols (2022)